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Table 3. Information needs at follow-up by randomised group. * P-values from Fisher’s exact test reported due to low cell frequencies. 
 
 TFU HFU  
 Yes No Yes No P 
Q17: Information about the cancer diagnosis?   6 (5·3%) 108 (94·7%) 4 (3·5%) 110 (96·5%) 0·75* 
Q18: Information about the different types of treatment, including side 
effects? (e.g. surgery, chemotherapy, radiotherapy 
2 (1·.8%) 109 (98·2%) 1 (0·9%) 110 (99·1%) 1·0* 
Q19: Information about whether your children or other members of the 
family are at risk of getting endometrial (womb) cancer? 
16 (14·3%) 96 (85·7%) 31 (27·7%) 81 (72·3%) 0·10 
Q20: Information about how the treatment may have affected your feelings 
about your body, your sexual attractiveness and sexual function 
7 (6·3%) 105 (93·8%) 12 (10·8%) 99 (89·2%) 0·80 
Q21: Information about caring for yourself? (e.g. diet, support groups, 
finances, psychological support) 
10 (8·8%) 103 (91·2%) 14 (12·4%) 99 (87·6%) 0·12 
Q22: Have you had any concerns about how your family are coping with 
your diagnosis 
4 (3·5%) 110 (96·5%) 5 (4·5%) 106 (95·5%) 0·30 
Q23: Do you need information about anything else not mentioned in 
questions 17-22? 
1 (0·9%) 111 (99·1%) 2 (1·8%) 111 (98·2%) 1·0* 
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